Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

PSA Level Greater Than Two 1Hormone Sensitive Prostate Cancer 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leuprolide × 30 days × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

NCT00544830 2026-05-15

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
29 enrolled 12 charts
Genitourinary

PSA Level Greater Than Two

Data powered by HemOnc (CC BY 4.0) Colophon âš¡